Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-HER2/HER3 Dendritic Cell Vaccine and Pembrolizumab in Breast Cancer with Brain Metastasis
NCT04348747Phase 2Recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2022
- Primary completion
- May 2028
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of anti-HER2/HER3 dendritic cell vaccine in breast cancer, brain metastasis (BM), sponsored by Roswell Park Comprehensive Cancer Center. Started Dec 2022; status: recruiting.
02
Drugs
anti-HER2/HER3 dendritic cell vaccine
03
Conditions
breast cancerbrain metastasis (BM)
Beyond the preview
Go deeper on NCT04348747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04348747.